These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The clinical use of levodopa in the treatment of Parkinson's disease. McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056 [No Abstract] [Full Text] [Related]
3. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease. De Letter M; Santens P; De Bodt M; Van Maele G; Van Borsel J; Boon P Clin Neurol Neurosurg; 2007 Jul; 109(6):495-500. PubMed ID: 17509751 [TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease. Muenter MD Neurology; 1970 Dec; 20(12):6-13. PubMed ID: 4924343 [No Abstract] [Full Text] [Related]
9. A double-blind controlled study of MK-486 in Parkinson's disease. Schwartz AM; Olanow CW; Spencer A Trans Am Neurol Assoc; 1973; 98():301-3. PubMed ID: 4594189 [No Abstract] [Full Text] [Related]
10. The causes of abnormal pulmonary function in Parkinson's disease. Obenour WH; Stevens PM; Cohen AA; McCutchen JJ Am Rev Respir Dis; 1972 Mar; 105(3):382-7. PubMed ID: 5011667 [No Abstract] [Full Text] [Related]
11. [L-Dopa therapy in Parkinson's disease. A double-blind study]. Worm-Petersen J; Dupont E; Mikkelsen B Ugeskr Laeger; 1971 Nov; 133(47):2321-6. PubMed ID: 4944651 [No Abstract] [Full Text] [Related]
12. Clinical effects of para-chlorophenylalanine in Parkinson's disease. Van Woert MH; Ambani LM; Levine RJ Dis Nerv Syst; 1972 Dec; 33(12):777-80. PubMed ID: 4272666 [No Abstract] [Full Text] [Related]
13. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders. Timberlake WH Neurology; 1970 Dec; 20(12):31-5. PubMed ID: 4924342 [No Abstract] [Full Text] [Related]
14. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders. Timberlake WH Neurology; 1970 Dec; 20(12):Suppl:31-5. PubMed ID: 4921586 [No Abstract] [Full Text] [Related]
15. Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa. Pal PK; Sathyaprabha TN; Tuhina P; Thennarasu K Mov Disord; 2007 Feb; 22(3):420-4. PubMed ID: 17230476 [TBL] [Abstract][Full Text] [Related]
16. Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease. Schwab RS; England AC Trans Am Neurol Assoc; 1969; 94():85-90. PubMed ID: 4907453 [No Abstract] [Full Text] [Related]
17. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease. Muenter MD Neurology; 1970 Dec; 20(12):Suppl:6-13. PubMed ID: 4921587 [No Abstract] [Full Text] [Related]
18. Levodopa in parkinson's disease--Australian collaborative trial. Selby G Med J Aust; 1973 Mar; 1(12):577-85. PubMed ID: 4700544 [No Abstract] [Full Text] [Related]
20. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor]. Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743 [No Abstract] [Full Text] [Related] [Next] [New Search]